RNA interference technology for anti-VEGF treatment

Expert Opinion on Drug Delivery

Volumn 11, Issue 9, 2014, Pages 1471-1480

  Chen, Shun ^a   Feng, Jia ^a   Ma, Liuqing ^a   Liu, Zhenguo ^a   Yuan, Weien ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Age related macular degeneration; Angiogenesis; Anti VEGF; Gene delivery; RNA interfering; Small interfering RNA; Tumor; VEGF

Indexed keywords

ALVN VSP 02; ALVN VSP02; BEVASIRANIB; MONOCLONAL ANTIBODY; PF 04523655; SIRNA 027; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

DRUG EFFICACY; GENE ACTIVITY; GENE TARGETING; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN TARGETING; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; SOLID TUMOR;

AGE-RELATED MACULAR DEGENERATION; ANGIOGENESIS; ANTI-VEGF; GENE DELIVERY; RNA INTERFERING; SMALL INTERFERING RNA; TUMOR; VEGF;

ANIMALS; ANTIBODIES, MONOCLONAL; HALF-LIFE; HUMANS; NEOPLASMS; RETINAL DISEASES; RNA INTERFERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84906315241     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.926886     Document Type: Review

References (93)

1. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000;407(6801):242-8
2. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
3. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380(6573):435-9
4. Ferrara N, Carver Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380(6573):439-42
5. Gerber H-P, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5(6):623-8
6. Bassett DL. The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle. Am J Anat 1943;73(2):251-91
7. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6
8. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37(5):855-68
9. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146(5):1029
10. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438(7070):967-74
11. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin Cancer Res 2006;12(17):5018-22
12. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40
13. Pieramici D, Rabena M. Anti-VEGF therapy: Comparison of current and future agents. Eye (Lond) 2008;22(10):1330-6
14. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: Reassessing the target. Cancer Res 2012;72(8):1909-14
15. Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011;12(5):329-40
16. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013;12(11):967-77
17. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219(4587):983-5
18. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161(2):851-8
19. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246(4935):1309-12
20. Olofsson B, Pajusola K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996;93(6):2576-81
21. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15(2):290
22. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998;95(2):548-53
23. Lyttle DJ, Fraser KM, Fleming SB, et al. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 1994;68(1):84-92
24. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991;88(20):9267-71
25. Ogawa S, Oku A, Sawano A, et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998;273(47):31273-82
26. Wise LM, Veikkola T, Mercer AA, et al. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc Natl Acad Sci USA 1999;96(6):3071-6
27. Semenza GL. Angiogenesis ischemic and neoplastic disorders. Annu Rev Med 2003;54(1):17-28
28. Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 2001;280(6):C1367-C74
29. Safran M, Kaelin WG. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003;111(6):779-83
30. Krüssel JS, Behr B, Milki AA, et al. Vascular endothelial growth factor (VEGF) mRNA splice variants are differentially expressed in human blastocysts. Mol Hum Reprod 2001;7(1):57-63
31. Frank S, Hübner G, Breier G, et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995;270(21):12607-13
32. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 1994;269(9):6271-4
33. Warren RS, Yuan H, Matli MR, et al. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 1996;271(46):29483-8
34. Brugarolas J, Kaelin Jr, WG. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 2004;6(1):7-10
35. Vincenti V, Cassano C, Rocchi M, Persico MG. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21. 3. Circulation 1996;93(8):1493-5
36. Houck KA, Ferrara N, Winer J, et al. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5(12):1806-14
37. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266(18):11947-54
38. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001;114(5):853-65
39. Bates DO, Cui T-G, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002;62(14):4123-31
40. Lange T, Guttmann-Raviv N, Baruch L, et al. VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. J Biol Chem 2003;278(19):17164-9
41. Jingjing L, Xue Y, Agarwal N, Roque RS. Human Müller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1999;40(3):752-9
42. Poltorak Z, Cohen T, Sivan R, et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997;272(11):7151-8
43. Houck KA, Leung D, Rowland A, et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992;267(36):26031-7
44. Park JE, Keller G-A, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4(12):1317
45. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275(5302):964-6
46. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18(1):4-25
47. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90(22):10705-9
48. Shen J, Samul R, Silva R, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2005;13(3):225-34
49. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92(6):735-45
50. Karkkainen MJ, Mäkinen T, Alitalo K. Lymphatic endothelium: A new frontier of metastasis research. Nat Cell Biol 2002;4(1):E2-5
51. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391(6669):806-11
52. B D. Advanced Information: RNA interference. Nobel Media AB: Nobelprize.org [website on Internet]. Available from: Http:/wwwnobelprizeorg/ nobel-prizes/medicine/laureates/2006/ advancedhtml [Accessed 8 November 2012
53. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference- based therapeutics. Nature 2009;457(7228):426-33
54. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat Chem Biol 2006;2(12):711-19
55. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov 2009;8(2):129-38
56. Zhang L, Yang N, Mohamed-Hadley A, et al. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-Angiogenesis gene therapy of cancer. Biochem Biophys Res Commun 2003;303(4):1169-78
57. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69(Suppl 3):11-16
58. Murata N, Takashima Y, Toyoshima K, et al. Anti-Tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J Control Release 2008;126(3):246-54
59. Kanazawa T, Sugawara K, Tanaka K, et al. Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptidemodified MPEG-PCL nanomicelles. Eur J Pharm Biopharm 2012;81(3):470-7
60. Kim SH, Jeong JH, Lee SH, et al. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release 2008;129(2):107-16
61. Kim WJ, Christensen LV, Jo S, et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther 2006;14(3):343-50
62. Takei Y, Kadomatsu K, Yuzawa Y, et al. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004;64(10):3365-70
63. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-Targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32(19):e149-e49
64. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs shRNA: Similarities and differences. Adv Drug Deliv Rev 2009;61(9):746-59
65. Guan H, Zhou Z, Wang H, et al. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewings sarcoma growth in a xenograft mouse model. Clin Cancer Res 2005;11(7):2662-9
66. Shibata M, Morimoto J, Shibata E, Otsuki Y. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther 2008;15(12):776-86
67. Kim B, Tang Q, Biswas PS, et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: Therapeutic strategy for herpetic stromal keratitis. Am J Pathol 2004;165(6):2177-85
68. Salva E, Akbuga J. In vitro silencing effect of chitosan nanoplexes containing siRNA expressing vector targeting VEGF in breast cancer cell lines. Pharmazie 2010;65(12):896-902
69. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105(8):R15
70. Lee C-G, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60(19):5565-70
71. Niola F, Evangelisti C, Campagnola L, et al. A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol Ther 2006;5(2):174-9
72. Zhang Y, Schwerbrock NM, Rogers AB, et al. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther 2013;21(8):1559-69
73. Li S-D, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 2008;16(5):942-6
74. Chen Y, Zhu X, Zhang X, et al. Nanoparticles modified with tumortargeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010;18(9):1650-6
75. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003;9(5):210-16
76. Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004;24(1):132-8
77. Dejneka NS, Wan S, Bond OS, et al. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis 2008;14:997
78. Singerman L. Combination therapy using the small interfering RNA bevasiranib. Retina 2009;29(6):S49-50
79. Kaiser PK, Symons R, Shah SM, et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 2010;150(1):33-9; e2
80. Shoshani T, Faerman A, Mett I, et al. Identification of a novel hypoxiainducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 2002;22(7):2283-93
81. Brafman A, Mett I, Shafir M, et al. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest Ophthalmol Vis Sci 2004;45(10):3796-805
82. Yoshida T, Mett I, Bhunia AK, et al. Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema. Nat Med 2010;16(7):767-73
83. Nguyen QD, Schachar RA, Nduaka CI, et al. Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci 2012;53(12):7666-74
84. Nguyen Q, Schachar R, Nduaka C, et al. Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (Lond) 2012;26(8):1099-105
85. Sarli V, Giannis A. Targeting the kinesin spindle protein: Basic principles and clinical implications. Clin Cancer Res 2008;14(23):7583-7
86. Gollob J, Infante J, Shapiro G, et al. Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. J Clin Oncol 2010;28(15 Suppl):abstract 3042
87. Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013;3(4):406-17
88. Gerber H-P, Kowalski J, Sherman D, et al. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000;60(22):6253-8
89. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94(6):715-25
90. Tsuzuki Y, Fukumura D, Oosthuyse B, et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha hypoxia response element VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 2000;60(22):6248-52
91. Kleinman ME, Yamada K, Takeda A, et al. Sequence-And target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452(7187):591-7
92. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-Target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010;9(1):57-67
93. Salva E, Kabasakal L, Eren F, et al. Local delivery of chitosan/VEGF siRNA nanoplexes reduces angiogenesis and growth of breast cancer in vivo. Nucleic Acid Ther 2012;22(1):40-8.